{"a":[{"_":"SK pens $315M pact with fellow South Korean company for Parkinson’s prospect","$":{"href":"/biotech/sk-pens-315m-pact-fellow-south-korean-company-parkinsons-prospect","hreflang":"en"}}]}

Summary

SK Biopharmaceuticals entered a $314.8 million biobucks deal with a fellow South Korean drug developer to acquire a preclinical Parkinson's disease therapy, adding a second such candidate to its pipeline.